JP2021516957A5 - - Google Patents

Info

Publication number
JP2021516957A5
JP2021516957A5 JP2020546320A JP2020546320A JP2021516957A5 JP 2021516957 A5 JP2021516957 A5 JP 2021516957A5 JP 2020546320 A JP2020546320 A JP 2020546320A JP 2020546320 A JP2020546320 A JP 2020546320A JP 2021516957 A5 JP2021516957 A5 JP 2021516957A5
Authority
JP
Japan
Prior art keywords
pcpv
composition
cancer
gene
antigen
Prior art date
Application number
JP2020546320A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019170820A5 (https=
JP2021516957A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/055744 external-priority patent/WO2019170820A1/en
Publication of JP2021516957A publication Critical patent/JP2021516957A/ja
Publication of JPWO2019170820A5 publication Critical patent/JPWO2019170820A5/ja
Publication of JP2021516957A5 publication Critical patent/JP2021516957A5/ja
Priority to JP2024001510A priority Critical patent/JP2024050588A/ja
Pending legal-status Critical Current

Links

JP2020546320A 2018-03-07 2019-03-07 パラポックスウイルスベクター Pending JP2021516957A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024001510A JP2024050588A (ja) 2018-03-07 2024-01-09 パラポックスウイルスベクター

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18305237 2018-03-07
EP18305237.2 2018-03-07
EP18306424.5 2018-10-31
EP18306424 2018-10-31
PCT/EP2019/055744 WO2019170820A1 (en) 2018-03-07 2019-03-07 Parapoxvirus vectors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024001510A Division JP2024050588A (ja) 2018-03-07 2024-01-09 パラポックスウイルスベクター

Publications (3)

Publication Number Publication Date
JP2021516957A JP2021516957A (ja) 2021-07-15
JPWO2019170820A5 JPWO2019170820A5 (https=) 2022-03-15
JP2021516957A5 true JP2021516957A5 (https=) 2022-03-15

Family

ID=65628796

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020546320A Pending JP2021516957A (ja) 2018-03-07 2019-03-07 パラポックスウイルスベクター
JP2024001510A Pending JP2024050588A (ja) 2018-03-07 2024-01-09 パラポックスウイルスベクター

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024001510A Pending JP2024050588A (ja) 2018-03-07 2024-01-09 パラポックスウイルスベクター

Country Status (10)

Country Link
US (1) US12377142B2 (https=)
EP (1) EP3762020A1 (https=)
JP (2) JP2021516957A (https=)
CN (1) CN112512560A (https=)
AU (1) AU2019229653B2 (https=)
BR (1) BR112020018117A2 (https=)
CA (1) CA3093093A1 (https=)
IL (1) IL277161A (https=)
MX (1) MX2020009262A (https=)
WO (1) WO2019170820A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021258008A1 (en) * 2020-06-19 2021-12-23 Immunacor Llc Compositions and methods for treating and preventing viral infection
WO2023083951A1 (en) * 2021-11-10 2023-05-19 Aicuris Gmbh & Co. Kg Parapoxvirus for preparing for and treatment of respiratory syncytial virus infections
WO2024062098A1 (en) 2022-09-23 2024-03-28 Transgene Recombinant pseudocowpox virus encoding an interleukin-12
CN116121207B (zh) * 2023-02-08 2025-12-12 华南农业大学 一种表达猪圆环病毒3型Cap蛋白的重组羊口疮病毒及其制备方法和应用
WO2024178260A2 (en) * 2023-02-22 2024-08-29 Cornell University Systems and methods for heterologous gene expression by poxvirus vectors
CN116897887A (zh) * 2023-07-31 2023-10-20 湖南中医药大学 一种病毒性哮喘动物模型的构建方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6222020B1 (en) 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
GB9013750D0 (en) 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
FR2668064B1 (fr) 1990-10-23 1994-12-16 Transgene Sa Composition pharmaceutique pour le traitement ou la prevention d'une tumeur maligne.
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US5856153A (en) 1994-11-17 1999-01-05 Cayla Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases
CA2247336C (en) 1996-02-28 2008-06-17 Bayer Aktiengesellschaft Parapoxviruses containing foreign dna, their production and their use in vaccines
EP0904393A4 (en) 1996-03-29 1999-09-08 Univ Otago PARAPOXVIRUS VECTORS
CA2261989C (en) 1996-07-25 2008-09-30 Therion Biologics Corporation Recombinant pox virus for immunization against tumor-associated antigens
EP1012276A2 (en) 1997-02-24 2000-06-28 Therion Biologics Corporation Recombinant pox virus for immunization against muc1 tumor-associated antigen
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
FR2790955B1 (fr) 1999-03-19 2003-01-17 Assist Publ Hopitaux De Paris Utilisation d'oligonucleotides stabilises comme principe actif antitumoral
AU1071701A (en) 1999-09-29 2001-04-30 Trustees Of The University Of Pennsylvania, The Methods for rapid peg-modification of viral vectors, compositions for enhanced gene transduction, compositions with enhanced physical stability, and uses therefor
US7456009B2 (en) 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
KR20040074067A (ko) 2001-12-10 2004-08-21 버베리안 노딕 에이/에스 폭스바이러스를 포함하는 제형 및 폭스바이러스를포함하는 안정한 조성물을 제조하기 위한 방법
CA2431349A1 (en) * 2002-06-06 2003-12-06 Xiao-Dan Yao Method of producing a recombinant virus
US7262045B2 (en) 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
WO2005007857A1 (en) 2003-07-21 2005-01-27 Transgene S.A. Polypeptide having an improved cytosine deaminase activity
CA2573204C (en) 2004-07-13 2011-09-20 Aicuris Gmbh & Co. Kg Parapoxviruses in combination with other antiviral agents for the treatment of hiv/aids
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
US20060205080A1 (en) 2005-03-01 2006-09-14 David Frey Formulations for therapeutic viruses having enhanced storage stability
CN101360821A (zh) 2005-11-21 2009-02-04 圣诺菲·帕斯图尔有限公司 重组病毒的稳定制剂
HUE030533T2 (hu) * 2006-06-20 2017-05-29 Transgene Sa Eljárás poxvírusok és poxvírus-készítmények elõállítására
WO2008092854A2 (en) 2007-01-30 2008-08-07 Transgene S.A. Papillomavirus e2 polypeptide used for vaccination
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
PT103865A (pt) 2007-10-25 2009-05-15 Univ De Coimbra Nano-transportadores de base lipídica para entrega direccionada de vectores virais e processo para a sua produção
CA2705869C (en) 2007-11-19 2012-10-30 Philippe Erbs Poxviral oncolytic vectors
CN103080415B (zh) 2010-07-01 2016-08-10 诺维信公司 纸浆的漂白
RU2013102413A (ru) 2010-07-20 2014-08-27 ЭйЭйч ЮЭсЭй 42 ЭлЭлСи Парапоксвирусные векторы
TWI623618B (zh) 2011-07-12 2018-05-11 傳斯堅公司 Ｈｂｖ聚合酶突變體
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
AU2015357225B2 (en) 2014-12-01 2020-04-09 Transgene Sa Stable liquid vaccinia virus formulations
ES3011733T3 (en) * 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
DE102015111756A1 (de) 2015-07-20 2017-01-26 Eberhard Karls Universität Tübingen Medizinische Fakultät Rekombinanter Orf-Virus-Vektor
WO2018031694A1 (en) 2016-08-09 2018-02-15 City Of Hope Chimeric poxvirus compositions and uses thereof

Similar Documents

Publication Publication Date Title
JP2021516957A5 (https=)
TWI850282B (zh) 用於治療癌症之質體建構體和使用方法
AU2022203309B2 (en) Recombinant MVA or MVADELE3L expressing human Flt3L and use thereof as immuno-therapeutic agents against solid tumors
EP2212696B1 (en) Systems and methods for viral therapy
US10646557B2 (en) Vaccine composition
JP6794442B2 (ja) 新規な遺伝子組換えワクシニアウイルス
JP7025339B2 (ja) 癌免疫療法のための、チミジンキナーゼの欠失を伴い、ヒトｆｌｔ３ｌまたはｇｍ－ｃｓｆの発現を伴うかまたは伴わない、複製可能な弱毒化ワクシニアウイルス
JP2024050588A5 (https=)
JP7438552B2 (ja) 注射用医薬品、注射用調製物、および注射用医薬品の製造における使用
TWI851676B (zh) 溶瘤病毒用於治療癌症之用途
CN105031618A (zh) 用于细胞因子递送的穹窿体复合物
JP2021533789A5 (https=)
CA3073310A1 (en) Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an antibody
JP2021517814A (ja) 免疫チェックポイント遮断を発現する癌免疫療法のための腫瘍溶解性ワクシニアウイルス
JPWO2019170820A5 (https=)
Shakiba et al. Recombinant strains of oncolytic vaccinia virus for cancer immunotherapy
WO2024216669A1 (zh) 具有多种免疫调节因子的增强型溶瘤病毒及其制备方法和应用
US20230277624A1 (en) Methods of determining responsiveness to cancer immunotherapy
KR20210151002A (ko) HveC의 세포외 도메인과 암세포 표적화 영역의 융합 단백질을 발현할 수 있는 발현 카세트를 가지는 재조합 헤르페스 심플렉스 바이러스 및 그 용도
CN121653082A (zh) 一种重组溶瘤痘苗病毒、制备方法及在制备用于预防或治疗肿瘤的药物中的应用
WO2024062098A1 (en) Recombinant pseudocowpox virus encoding an interleukin-12
CN119367516A (zh) 一种免疫调节因子组合物及其应用
CN118556081A (zh) 用于癌症治疗的编码免疫刺激蛋白的重组正痘病毒载体